The Europe generic drug market is currently witnessing strong growth. Generic drugs are pharmaceutical drugs with an equivalent therapeutic effect as their branded counterparts. These drugs are also identical to the innovator drug in terms of safety, strength, quality, dosage route of administration and intended usage. Unlike branded drugs, generic drugs are cost-efficient and do not require hefty investments on marketing campaigns or clinical studies.
Governments of various countries in Europe are undertaking initiatives to maintain a stable supply of medicines and support the Supplementary Protection Certificate (SPC) manufacturing waiver. This represents one of the significant factors propelling the growth of the generic drug market in Europe. Other factors driving the market are low production costs of generic drugs compared to their counterparts. This is attracting manufacturers to make capital investments in the industry. However, due to the surge in the coronavirus disease (COVID-19) cases, governing agencies have implemented lockdown restrictions in several countries. This has disrupted the manufacturing of generic drugs in Europe, but the market will experience growth once the cases start subsiding and lockdown restrictions are uplifted. Looking forward, the market is expected to continue its strong growth during the forecast period (2021-2026).
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe generic drug market report, along with forecasts for growth at the region level from 2021-2026. Our report has categorized the market based on region, segment, therapy area, drug delivery and distribution channel.
Breakup by Segment:
Breakup by Therapy Area:
Breakup by Drug Delivery:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at